Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol

NCT ID: NCT00678756

Last Updated: 2010-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Exploration of antipsoriatic effects of UVB-therapy +/- CYP-inhibitor Ketokonazol on affected psoriatic skin

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketokonazol 2% cream

twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week

Intervention Type DRUG

UVB-radiation 311nm

3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nizoral cream UVB Radiation, phototherapy, narrow-band ultraviolet B phototherapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age: 18- 80
* diagnosis of psoriasis vulgaris (mild- middle)
* no other current antipsoriatic therapy (systemic/topical)
* at least 5 psoriatic areas of 5x5 cm

Exclusion Criteria

* pregnancy/nursing mothers
* women in reproductive age without adequate contraception
* severe and acute forms of psoriasis vulgaris
* patients receiving systemic or topical antipsoroatic treatment in past 3 month
* UV-therapy in past 3 month
* patients having a positive anamnesis for squamous cell carcinoma, malignant melanoma, basalioma
* epilepsy
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Technische Universität Dresden

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Technical University Dresden, Department of Dermatology

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gottfried Wozel, Prof. Dr.med

Role: PRINCIPAL_INVESTIGATOR

Department of Dermatology, Medical Faculty, Technical University Dresden, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Dermatology, Medical Faculty, TU Dresden

Dresden, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TUD-VITAKET

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Topical Thymoquinone in Psoriasis Vulgaris
NCT06508372 NOT_YET_RECRUITING NA
Scalp Psoriasis Treatment With a Fiber Optic Comb
NCT00007293 COMPLETED PHASE1/PHASE2